Zika Virus Vaccine Candidate from Japan
mRNA-based or DNA vaccine platform for Zika flavivirus prevention, in clinical stages. Fits HTS 3002.49.0050 as other virus culture-derived prophylactic product via biotech processes.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Classify as gene therapy if applicable; special USDA permits for vectors
• Document trial phase and IRB approval; frozen shipment standard